Psychiatry AtlasMedication guide · United States

Antipsychotic medicine

Cariprazine (Vraylar)

Generic name
cariprazine (as cariprazine hydrochloride)
Brand names
Vraylar
Medication class
Antipsychotic medicine
Forms covered
Vraylar oral capsules

Article updated: 2026-10-24 · Sources last checked: 2026-11-05

Medication Safety Alerts

FDA Boxed Warning

Vraylar oral capsules.

Older adults with dementia-related psychosis have an increased risk of death with antipsychotic treatment; Vraylar is not approved for that condition. Its label also warns that antidepressants increase suicidal thoughts and behaviors in pediatric and young adult patients. Monitor all antidepressant-treated patients for worsening mood and suicidal thinking.

Cariprazine (Vraylar) treats schizophrenia, bipolar I mood episodes and, with an antidepressant, major depression. Approved ages differ: schizophrenia from 13, bipolar mania or mixed episodes from 10, and depression uses in adults only.

What to expect: Fuller benefit can take several weeks or longer.

Warning signs
Sources last checked:
2026-11-05

What is this medicine used for?

FDA-approved uses

  • Schizophrenia — Adults and pediatric patients aged 13 years and older. Pediatric dosing has a lower maximum and separate titration.Vraylar oral capsules.
  • Acute manic or mixed episodes associated with bipolar I disorder — Adults and pediatric patients aged 10 years and older. Age-specific schedules and maximum doses apply.Vraylar oral capsules.
  • Depressive episodes associated with bipolar I disorder — Adults. Adult bipolar depression; pediatric effectiveness is not established.Vraylar oral capsules.
  • Adjunctive treatment of major depressive disorder — Adults. Added to an antidepressant; not an approval for pediatric depression or antidepressant replacement.Vraylar oral capsules.

What should I expect?

Fuller benefit can take several weeks or longer. Because active breakdown products leave the body slowly, the effects of a new dose may continue to develop for weeks.

Report new restlessness or movement symptoms even if they start well after a dose change. Continue planned monitoring after reductions or stopping, and contact the prescriber if improvement is not developing.

How do I take it safely?

Take once daily with or without food. Follow the exact dose for the diagnosis and age; adult schedules must not be transferred to children.

Monitor weight, blood pressure, glucose, blood fats, restlessness and other movement changes. Blood-cell counts may be needed for people with previous low counts. Continue monitoring for several weeks after dose changes or stopping.

Have all medicines checked. Certain antibiotics, antifungals and other medicines that inhibit CYP3A4 require substantial dose changes; CYP3A4 inducers are not recommended. Pediatric interaction instructions differ from adult instructions.

Discuss severe kidney or liver disease, previous seizures, heart disease, swallowing problems, dehydration or falls. Severe kidney or liver impairment is not a recommended-use setting in the current label.

Alcohol and sedating or blood-pressure medicines may add impairment or fainting. Do not drive until you know the effects, and avoid overheating or dehydration.

For a missed dose, take it when remembered unless the next is close, then skip it; never double. Plan stopping or switching with the prescriber rather than relying on its long persistence to protect against missed treatment.

Discuss pregnancy planning and breastfeeding. Drug effects may persist after stopping; late-pregnancy antipsychotic exposure can affect newborn movement, feeding or breathing. The boxed dementia mortality warning remains applicable.

Do not use after a known allergy to cariprazine or product ingredients.

What side effects should I know about?

  • Akathisia, other movement symptoms or restlessness.
  • Nausea, sleep changes, indigestion, constipation, fatigue or dizziness depending on indication.

Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.

Which warning signs need help?

  • FDA boxed warnings address increased mortality in older adults with dementia-related psychosis and increased suicidal thoughts and behaviors in pediatric and young adult antidepressant-treated patients. Vraylar is not approved for dementia-related psychosis. Monitor all patients treated for depression for worsening mood or suicidal thinking; the newer pediatric schizophrenia and mania approvals do not establish pediatric depression approval.
  • High fever with severe muscle stiffness, confusion or unstable pulse can be neuroleptic malignant syndrome; get emergency care.
  • Report new involuntary movements promptly because they can persist. Severe restlessness, falls, fainting, fever with infection symptoms or swallowing difficulty also needs assessment.
  • Marked thirst, frequent urination, severe weakness or confusion may signal high blood sugar; seek prompt assessment. Adverse effects can appear weeks after a dose change.
  • New suicidal thoughts or a severe mood or behavior change needs immediate clinical contact; get emergency help if someone cannot stay safe.
  • Get emergency help for trouble breathing, swelling of the tongue or throat, collapse, a seizure or inability to wake. Suspected overdose needs immediate poison-center or emergency advice; do not wait for symptoms.

What else should I know to stay safe?

  • Do not use after cariprazine or ingredient allergy. Severe kidney or liver impairment is not a recommended-use setting. Certain enzyme-blocking medicines require substantial dose changes; enzyme-inducing medicines are not recommended, and pediatric interaction instructions differ from adult instructions.
  • Monitor weight, blood pressure, glucose, blood fats and movements; previous low white-cell counts may require blood tests. Review seizures, heart disease, swallowing problems and falls. Avoid alcohol, unreviewed sedatives, dehydration, overheating and driving while impaired.
  • Plan stopping or switching and continue monitoring for several weeks because active breakdown products persist. Discuss pregnancy planning and breastfeeding; effects can remain after stopping, and late-pregnancy exposure can affect newborn movement, feeding or breathing.

Urgent help and crisis support · Emergency & Crisis Resources (US)

What can help day to day?

  • A delayed side effect can still be related to a recent dose change. Cariprazine’s active breakdown products remain in the body for weeks.
  • A lower dose may be appropriate for one diagnosis than another. The maximum used for schizophrenia is not the maximum for depression.
  • Feeling driven to move may be a medication effect called akathisia. Describing it clearly helps the prescriber distinguish it from anxiety or worsening illness.

How does it work?

Cariprazine changes how brain cells respond to dopamine and serotonin, two chemical messengers. It partly activates some receptors, the proteins that receive those messages, and blocks others. Its effects also depend on active substances made as the body processes it, which can remain present for a long time.

Explore medication science

How was this medicine developed?

Vraylar first received FDA approval in 2015. Later approvals added adult depression uses and, in December 2025, schizophrenia from age 13 and bipolar I manic or mixed episodes from age 10. Those pediatric changes did not approve pediatric depression treatment.

How do I say the name?

Cariprazine: kar-ip-rah-zeen. Capital letters show the stressed syllable.

Sources and References

Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.

  1. Vraylar: current prescribing information
  2. Vraylar: FDA approval and supplement history
  3. Cariprazine: patient medicine information
  4. Vraylar: FDA label with current pediatric populations
  5. Vraylar: Package Insert / Prescribing Information / MOA
  6. Rexulti: current prescribing information
  7. Cariprazine: verified neutral parent, PubChem CID 11154555
  8. A qualitative investigation into the effects of akathisia - Health Research Authority
  9. Extrapyramidal side effects- Management
  10. Anxiety and panic attacks - NHS
  11. Agitation: MedlinePlus Medical Encyclopedia
  12. Frequently Asked Questions about Labeling for Prescription Medicines | FDA
  13. NIMH: Understanding psychosis

Giving medicine safely to children: family guide (PDF, 3 pages)

How information is checked

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top